Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia $(AML.AU)$ for both therapies. The presentation highlighted Galinpepimut-S $(GPS.AU)$, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival $(OS)$ notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.
Comments